- Home
- ICU vs BOLT Comparison
ICU vs BOLT Comparison
Compare ICU & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICU | BOLT |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ICU | BOLT |
|---|---|---|
| Price | $2.26 | $5.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 119.4K | 30.4K |
| Earning Date | 03-26-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $881,000.00 | ★ $5,195,000.00 |
| Revenue This Year | $1,043.70 | N/A |
| Revenue Next Year | $54.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1195.59 | N/A |
| 52 Week Low | $2.20 | $4.41 |
| 52 Week High | $25.70 | $10.50 |
Technical Indicators
Market Signals| Indicator | ICU | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 36.14 |
| Support Level | $2.31 | $5.35 |
| Resistance Level | $2.74 | $6.40 |
| Average True Range (ATR) | 0.19 | 0.52 |
| MACD | -0.09 | -0.18 |
| Stochastic Oscillator | 21.57 | 2.23 |
Price Performance
Historical ComparisonAbout ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.